Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Not applicable Interventional

Viveve Geneveve Treatment of the Vaginal Introitus to Evaluate Safety and Efficacy

ClinicalTrials.gov ID: NCT03479229

Public ClinicalTrials.gov record NCT03479229. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT03479229
Recruitment status
Completed
Study type
Interventional
Phase
Not applicable
Lead sponsor
Viveve Inc.
Industry
Enrollment
250 participants

Conditions and interventions

Interventions

  • Geneveve Treatment Device
  • Sham Treatment Device

Device

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 19, 2018
Primary completion
Mar 14, 2020
Completion
Mar 14, 2020
Last update posted
May 18, 2020

2018 – 2020

United States locations

U.S. sites
19
U.S. states
16
U.S. cities
19
Facility City State ZIP Site status
VIVEVE II Study Site La Mesa California 91942
VIVEVE II Study Site Orange California 92868
VIVEVE II Study Site Denver Colorado 80209
VIVEVE II Study Site Washington D.C. District of Columbia 20036
VIVEVE II Study Site Lake Worth Florida 33461
VIVEVE II Study Site Plantation Florida 33324
VIVEVE II Study Site West Palm Beach Florida 33409
VIVEVE II Study Site Atlanta Georgia 30342
VIVEVE II Study Site Idaho Falls Idaho 83404
VIVEVE II Study Site Kalamazoo Michigan 49009
VIVEVE II Study Site St Louis Missouri 63117
VIVEVE II Study Site Omaha Nebraska 68114
VIVEVE II Study Site New Brunswick New Jersey 08901
VIVEVE II Study Site Albuquerque New Mexico 87131
VIVEVE II Study Site New York New York 10038
VIVEVE II Study Site Raleigh North Carolina 27612
VIVEVE II Study Site Columbus Ohio 43221
VIVEVE II Study Site Jackson Tennessee 38305
VIVEVE II Study Site Tacoma Washington 98042

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03479229, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 18, 2020 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03479229 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →